T ype 2 diabetes affects more than 23.6 million people in the United States alone. In 2007, total excess cost for diabetes totaled $174 billion. 1 Since the U.S. approval of metformin, multiple treatments have been discovered and implemented that have had a direct impact on the control of type 2 diabetes. Appropriate selection and use of these agents is paramount to successful treatment of the type 2 diabetic patient.
On October 17, 2006, the U.S. Food and Drug Administration approved sitagliptin (Januvia), the first oral dipeptidyl peptidase IV inhibitor (DPP-IV) for the treatment of type 2 diabetes.
2 DPP-IV inhibitors are enhancers of incretin hormones, particularly glucagon-like peptide 1 (GLP-1), which stimulates postprandial insulin secretion, increases satiety, decreases gastric emptying, and inhibits glucagon secretion. GLP-1 is excreted into the circulation by the enteroendocrine L cells after a meal but is rapidly inactivated by DPP-IV. Long-term treatment with sitagliptin, which inhibits the degradation of GLP-1 by DPP-IV, has been shown to reduce glycosylated hemoglobin levels, fasting glucose levels, and postprandial glucose excursions. [3] [4] [5] [6] Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Sitagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, and sitagliptin has not been studied in combination with insulin. 7 Sitagliptin is available in 25 milligram (mg), 50 mg, and 100 mg tablets.
Multiple studies have been performed evaluating the pharmacokinetic properties of sitagliptin. [8] [9] [10] [11] Renal excretion is the primary mechanism of elimination for sitagliptin. Increases in sitagliptin area under the curve (AUC) have been shown to be less than 2-fold for patients with creatinine clearance (CrCl) 
B R I E F C O M M U N I C AT I O N
• There have been no studies reported in the medical literature regarding appropriate prescribing of sitagliptin based on label prescribing recommendations for renal function.
• The actual patient harm or effect on clinical biomarkers such as A1c associated with failure to adjust the dose of sitaglipitin based on renal function are unknown.
What is already known about this subject
• Based on assessment of renal function, pharmacist prescribing of the initial dose of sitagliptin was associated with 1 case (0.6%) of potentially inappropriate prescribing (under-dose) compared with 34 cases of potentially inappropriate prescribing (21 overdose and 13 under-dose) by nonpharmacists. The magnitude of the threat to patient safety or other clinical outcomes from this potentially inappropriate initial prescribing of sitagliptin is unknown.
agreement, was responsible for evaluation and treatment of diabetes and conditions associated with diabetes. The pharmacist had the authority to order laboratory tests, initiate medications, make referrals, and schedule follow-up when deemed necessary. The pharmacist in this clinic saw an average of 20 diabetic patients per day for 4 and a half days per week. Patients not seen in the diabetes disease management program received usual medical care for their type 2 diabetes from their nonpharmacist provider. This was a retrospective cross-sectional cohort analysis of all patients who received initial sitagliptin dosing by a provider in the internal medicine department from October 17, 2006, through June 5, 2008 . Initial dosing of sitagliptin was defined as the first time an order for sitagliptin was entered in the electronic medical record. Since changing to electronic medical records in 2003, handwritten prescriptions were not allowed. Every prescription for any medication had to be entered into the electronic medical record before a prescription could be validated and given to the patient. Data were extracted from the electronic medical records database. Data evaluated for GFR were recorded for the present study if determined at the time of initiation of sitagliptin, or if not available, a GFR within 60 days prior to initiation of sitaglipitin was allowed. The MDRD equation was used to estimate renal function because the MDRD formula is now recommended by the National Kidney Foundation to estimate GFR for staging of chronic kidney disease (CKD).
14 The MDRD equation was utilized for this study versus other methods to estimate renal function, because the source laboratory would report a GFR using the MDRD calculation on all reported basic metabolic profiles in an attempt to proactively evaluate and stage CKD. 15 Estimation of renal function using other methods, such as the Cockroft-Gault equation, did not frequently occur at our facility.
Only patients for whom sitagliptin was initiated by a provider in the department of internal medicine were included in this study.
■■ Results
Of 290 patients who received initial dosing of sitagliptin between October 17, 2006, and June 5, 2008, 13 patients (4.5%) received 25 mg; 29 patients (10.0%) received 50 mg; and 248 patients (85.5%) received 100 mg (Table 1) . Appropriate dose according to label instructions regarding renal function was found for 255 patients (87.9%, Table 2 ). For the 35 patients (12.1%) with potentially inappropriate initial dosing of sitagliptin, 21 were over-dosed and 14 were under-dosed (Table 2) .
There were 158 patients for whom sitagliptin was prescribed by a pharmacist, of which only 1 patient in the group with GFR > 50 ml per minute was not prescribed the appropriate dose (100 mg, Table 2 ). There were 132 patients for whom sitagliptin was prescribed by a nonpharmacist, of which 34 patients (25.8%) were prescribed sitagliptin doses that did not correspond to the label recommendations based on GFR values. between 50-80 milliliters (ml) per minute; 2.3-fold higher for CrCl ≥ 30-50 ml per minute; 3.8-fold higher for CrCl < 30 ml per minute; and 4.5-fold higher for patients with end stage renal disease (ESRD). 12 For this reason, sitagliptin dose adjustments are recommended by the manufacturer in the presence of renal dysfunction. Patients having CrCl of > 50 ml per minute should receive a dose of 100 mg per day; patients with CrCl ≥ 30-50 ml per minute should receive 50 mg; and patients with CrCl < 30 ml per minute should receive 25 mg of sitagliptin. 7 Recent data suggest that sitagliptin is well tolerated and provides effective glycemic control in patients with type 2 diabetes with moderate to severe renal insufficiency, including patients on dialysis. 13 To our knowledge, no data exist examining the potentially inappropriate dosing of sitagliptin based on manufacturer guidelines.
The primary objective of this study was to evaluate the prevalence of the potentially inappropriate initial dosing of sitagliptin using manufacturer recommendations at the time of first initiation using the 4-point Modification in Diet and Renal Disease (MDRD) formula as an estimate of creatinine clearance in an internal medicine department. The 4-point MDRD formula estimates glomerular filtration rate (GFR) using the serum creatinine, age, gender, and ethnicity of the patient:
[GFR (mL/min/1.73 m2) = 175 x (Scr)- The secondary objective was to evaluate the prevalence of potentially inappropriate dosing in patients for whom sitagliptin was initiated by a pharmacist versus patients in whom sitagliptin was initiated by a nonpharmacist prescriber.
This study received exempt status from the institutional review board (IRB) of the University of Tennessee Health Science Center.
■■ Methods
This study was conducted in the internal medicine department (consisting of 10 physicians, 4 nurse practitioners, 1 physician assistant, and 1 clinical pharmacist) within a private physicianowned multispecialty clinic of 62 physicians. The internal medicine department averaged 423 patient visits per week. The clinic patients were approximately 38% Medicare, 7% Medicaid, 54% commercial insurance, and 1% cash-pay. The internal medicine department developed a pharmacist-directed diabetes disease management program in 2000. The Diabetes Care Clinic was established as a way to standardize the treatment of the type 2 diabetic patient within the internal medicine department by incorporating evidence-based medicine with a goal of achieving the standards of care established by the American Diabetes Association. The pharmacist-directed diabetes disease management program was voluntary, with patient enrollment initiated when poor diabetic control was documented by a nonpharmacist provider (i.e., physician, physician assistant, or nurse practitioner).
The pharmacist, who worked under a collaborative practice
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pharmacist-managed diabetes management program versus usual care. Therefore, our study shows primarily that an opportunity exists in usual care to educate nonpharmacists about the prescribing information in the sitagliptin product label. However, it is also true that the adverse consequences in patients, or effects on intermediate biomarkers such as A1c, of not dosing sitagliptin according to renal function are unknown. Second, GFR can fluctuate in individuals, so it is hard to know if a dose of sitagliptin was truly inappropriate at the time of initiation. The uncertainty associated with determination of precise renal function is accompanied by uncertainty in categorizing patients based on somewhat arbitrary cut-off points for dose changes. For example, 25 patients had a GFR that was within 1 ml per minute of a range where a dosage adjustment would have been required by the label prescribing information for sitagliptin; these 25 patients were distributed nearly equally between the pharmacist group (n = 12) and the nonpharmacist group (n = 13).
Third, we used the MDRD formula, as now recommended by the National Kidney Foundation to estimate GFR for staging CKD 14 and acknowledge that the sitagliptin prescribing information mentions that "creatinine clearance can be estimated from serum creatinine using the Cockroft-Gault formula." 7 We relied on MDRD because every basic metabolic profile at our medical clinic includes a GFR value calculated by the 4-point MDRD equation as part of an initiative to proactively identify patients with CKD. Use of the MDRD equation has not been validated as a reliable estimation of renal function in monitoring drugs. 15 Few studies exist evaluating the comparison of the Cockroft-Gault equation with the MDRD equation in drug dosing. [18] [19] [20] Therefore, use of the MDRD equation represents current practice trends in our medical clinic but may not represent common practice in other medical facilities when adjusting medications according to patient renal function.
Fourth, the present study did not evaluate outcomes associated with presumably inappropriate dosing of sitagliptin. The
■■ Discussion
Treatment of diabetes has become multifaceted and increasingly more complicated. The choice of treatment should be based on current available guidelines with the initial treatment composed of diet and metformin as well-validated core (tier 1) therapy. 16 Additional treatment (tier 2) is left up to provider choice with options including sulfonylurea, pioglitazone, basal insulin, or GLP-1 enhancers. DPP-4 inhibitors such as sitagliptin are currently considered to be "other therapy." 16 The use of sitagliptin may be an attractive option for some patients given its glucosedependent mechanism of action and weight neutrality compared with some other agents. 6 Limited safety data currently exist regarding the use of sitagliptin. The most common side effects associated with sitagliptin are nasopharyngitis, urinary tract infections, headache, and gastrointestinal disturbances, with the latter seen more commonly with higher doses. [3] [4] [5] Postmarket hypersensitivity reactions, which include anaphylaxis, angioedema, and Stevens-Johnson syndrome, have been reported; 7 however, it is difficult to quantify this because of the anecdotal nature of the self-reported cases. A recent case report proposed a link between rhabdomyolysis secondary to an interaction between sitagliptin and lovastatin. Based on results from this study, an inappropriate initial dose of sitagliptin based on renal function was prescribed for 12.1% of patients (n = 35), with 21 (60.0%) over-dosed and 14 patients (40.0%) under-dosed. Patients who were seen by a nonpharmacist provider received a potentially inappropriate dose of sitagliptin 25.8% of the time for initiation of therapy. Only 1 patient with sitagliptin initiated by a pharmacist was given an inappropriate (under) dose.
Limitations
This study was a retrospective chart review that has many limitations. First, patients were not randomly assigned to the lack of outcomes data for A1c levels or actual patient harm associated with over-dosing or under-dosing according to renal function means that it is not possible from this study to determine if the dosing of sitagliptin was truly clinically inappropriate.
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■■ Conclusion
To our knowledge, this study is the first to investigate the initial dosing of sitagliptin prescribed by a pharmacist compared with nonpharmacist prescribers based on the prescribing information in the product label. The results from this study reveal that there is an apparent opportunity to improve the adherence of initial sitagliptin dosing to the label recommendations for dose adjustment according to renal function. Compared with nonpharmacist prescribers, patients who had sitagliptin dosing initiated by a pharmacist were more likely to receive the appropriate dose based on renal function. 
